Pharma back in focus for CLOs after Trump comments

capsule px230
By Sam Kerr
12 Jan 2017

The pharmaceuticals industry is back under the microscope of US CLO players after comments on drug pricing from president-elect Donald Trump hinted at a tougher environment for drug makers under a Trump presidency.

On January 11, the incoming president said that drug companies had “been getting away with murder” with regards to price hiking for too long.

Trump's comment sparked a selloff in some US pharmaceutical company stocks and has once again forced CLO investors and issuers to take a hard ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.